Kwality Pharma Q2FY27: consol PAT doubles YoY to ₹29 Cr, margins expand, guidance raised
PAT +105.6% YoY · revenue +63.2% · margins expanding
₹181.22 Cr
+63.2% YoY
₹29.03 Cr
+105.6% YoY
15.95%
+3.3pp YoY
₹27.93
Kwality Pharmaceuticals' consolidated revenue grew 63.2% YoY to ₹181.2 Cr in Q2 FY27 (up 11.6% QoQ from ₹162.4 Cr in Q1 FY27), while consolidated PAT more than doubled YoY — up 105.6% to ₹29.03 Cr from ₹14.12 Cr a year ago, and up 13.3% sequentially from ₹25.62 Cr. Basic EPS rose to ₹27.93 from ₹13.60 a year earlier. There were no exceptional items in either the current or year-ago quarter, so this is organic growth, not a one-off-driven print. Notably, the company's own MD&A states PAT "doubled to ₹50 crore from ₹25 crore," but that figure does not tie to the board-approved, auditor-reviewed P&L (consolidated PAT ₹29.03 Cr, standalone ₹29.02 Cr); ₹50.6 Cr instead matches this quarter's EBITDA (PBT + finance cost + depreciation), so the press language appears to have conflated the two — the filed statement, not the prose, is the number of record.
Q2 FY-2027 vs prior quarters
Net profit margin expanded to 16.0% from 12.6% a year ago and 15.7% last quarter, and EBITDA margin rose to roughly 27.8% (on total income) from about 23.4% in Q2 FY26, which management attributes to operating leverage and a richer product mix as cost of materials consumed eased as a share of revenue. Finance costs were roughly flat YoY (₹2.99 Cr vs ₹2.84 Cr) even as total borrowings rose to ₹146 Cr from ₹130 Cr at FY26-end, while depreciation grew in line with continuing capex.
The stock went into the print at ₹4,122.1, up 16.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
FY27 revenue ₹700+ Cr (reaffirmed from ₹650-700 range), EBITDA margins 26-27% unchanged. FY28-30 ambition: ₹1,500 Cr by FY30; hormone ₹150-200 Cr, biologics ₹200-250 Cr, oncology/generics sustained growth.
— This quarter: beat
Management raised FY27 revenue guidance to ₹720 Cr+ from the ₹700 Cr+ it had just reaffirmed last quarter (originally ₹650-700 Cr), while holding its EBITDA margin guidance at 26-27% — consistent with the quarter's delivered margin. H1FY27 consolidated revenue stands at ₹343.6 Cr, meaning H2 needs to average roughly ₹188 Cr a quarter to clear the new bar. There is no sell-side analyst coverage of the stock (zero analysts tracking it per AlphaSpread), so there is no street consensus to grade this print against. During the quarter the company received EU-GMP certification from Hungary for its Cephalosporin and Oncology manufacturing facilities, acquired 4 acres adjacent to its Amritsar campus to build "Unit 7" (envisaged with 4+ injectable and 6+ oral-solid-dosage lines), and completed bioequivalence studies for 19 products now ready for international regulatory filings — all cited by management as the basis for the guidance upgrade. Working capital discipline also improved, with the cash conversion cycle down to 130 days from 170 days in FY26.
W1
H2FY27 revenue needs to average ~₹188 Cr/quarter (vs ₹181 Cr in Q2) to clear the raised ₹720 Cr+ FY27 guidance off a ₹343.6 Cr H1 base
W2
EBITDA margin sustainability at 26-27% guided vs ~27.8% delivered in Q2, as Unit 7 capex begins
W3
Oncology manufacturing expansion completion targeted June 2027; Hormone facility licence audit now underway after construction completion
Informational and educational content only. Not investment advice.